Literature DB >> 20438288

Procalcitonin is useful in identifying bacteraemia among children with pneumonia.

Cristiana M Nascimento-Carvalho1, Maria-Regina A Cardoso, Aldina Barral, César A Araújo-Neto, Sylvie Guerin, Annika Saukkoriipi, Mika Paldanius, Raija Vainionpää, Pierre Lebon, Maija Leinonen, Olli Ruuskanen, Dominique Gendrel.   

Abstract

Empirical antibiotic use is prescribed in managing children with pneumonia worldwide. We assessed the usefulness of procalcitonin (PCT) and interferon-alpha (IFN-alpha) in differentiating viral from bacterial pneumonia. Among 159 hospitalized children, pneumonia was diagnosed based on clinical complaints plus pulmonary infiltrate. Aetiology was investigated for 9 viruses and 4 atypical and 3 typical bacteria. PCT and IFN-alpha were measured in the serum sample collected on admission. Eight patients had bacteraemic infections, 38 had non-bacteraemic typical infections, and 19 patients had atypical bacterial infections. Viral and unknown aetiology was established in 57 (36%) and 34 (21%) cases, respectively. Three patients with bacterial infection without collected blood culture were excluded. IFN-alpha (IU/ml) was detectable in 20 (13%) cases. The difference among median PCT values of the bacteraemic (4.22; 1.56-7.56), non-bacteraemic typical bacterial (1.47; 0.24-4.07), atypical bacterial (0.18; 0.06-1.03) and only viral (0.65; 0.11-2.22) subgroups was significant (p = 0.02). PCT was > or =2 ng/ml in 52 (33%) cases. The presence of IFN-alpha was associated with PCT <2 ng/ml (90% vs. 64%, p = 0.02). The negative predictive value (95% confidence interval) of PCT > or =2 ng/ml was 95% (89-100%), 89% (78-100%), 93% (85-100%) for differentiation of bacteraemic from viral, atypical bacterial and non-bacteraemic typical bacterial infection, respectively, and 58% (49-68%) for differentiation between bacterial and viral infection. PCT may be useful in identifying bacteraemia among children hospitalized with community-acquired pneumonia. IFN-alpha was uncommonly detected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438288     DOI: 10.3109/00365541003796775

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

2.  Detection of antibody responses against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins in children with community-acquired pneumonia: effects of combining pneumococcal antigens, pre-existing antibody levels, sampling interval, age, and duration of illness.

Authors:  I C Borges; D C Andrade; A-L Vilas-Boas; M-S H Fontoura; H Laitinen; N Ekström; P V Adrian; A Meinke; M-R A Cardoso; A Barral; O Ruuskanen; H Käyhty; C M Nascimento-Carvalho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-19       Impact factor: 3.267

3.  Value of procalcitonin for diagnosing perioperative pneumonia, urinary infections and superficial surgical site infections in patients undergoing primary hip and knee arthroplasty.

Authors:  Lixuan Zhang; Daozhang Cai; Hanming Guo
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

4.  Novel biomarkers to detect infection in revision hip and knee arthroplasties.

Authors:  Mathias Glehr; Joerg Friesenbichler; Günter Hofmann; Gerwin Alexander Bernhardt; Maximilian Zacherl; Alexander Avian; Reinhard Windhager; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2013-04-23       Impact factor: 4.176

5.  Procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia.

Authors:  Jérémie F Cohen; Alexander Leis; Thibault Lecarpentier; Josette Raymond; Dominique Gendrel; Martin Chalumeau
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

6.  Sensitivity and Specificity of Soluble Triggering Receptor Expressed on Myeloid Cells-1, Midregional Proatrial Natriuretic Peptide and Midregional Proadrenomedullin for Distinguishing Etiology and to Assess Severity in Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Maria Di Gangi; Fabio Cardinale; Eugenio Baraldi; Ilaria Corsini; Liviana Da Dalt; Pier Angelo Tovo; Antonio Correra; Alberto Villani; Oliviero Sacco; Laura Tenero; Piera Dones; Monia Gambino; Alberto Zampiero; Nicola Principi
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  Severity of Pneumonia in Under 5-Year-Old Children from Developing Countries: A Multicenter, Prospective, Observational Study.

Authors:  Thomas Bénet; Valentina Sanchez Picot; Shally Awasthi; Nitin Pandey; Ashish Bavdekar; Anand Kawade; Annick Robinson; Mala Rakoto-Andrianarivelo; Maryam Sylla; Souleymane Diallo; Graciela Russomando; Wilma Basualdo; Florence Komurian-Pradel; Hubert Endtz; Philippe Vanhems; Gláucia Paranhos-Baccalà
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

8.  Community-Acquired Pneumonia in the Conjugate Vaccine Era.

Authors:  Derek J Williams; Samir S Shah
Journal:  J Pediatric Infect Dis Soc       Date:  2012-11-06       Impact factor: 3.164

Review 9.  What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia?

Authors:  Andrew T Pavia
Journal:  Infect Dis Clin North Am       Date:  2012-12-12       Impact factor: 5.982

10.  Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.

Authors:  Chris Stockmann; Krow Ampofo; Jarrett Killpack; Derek J Williams; Kathryn M Edwards; Carlos G Grijalva; Sandra R Arnold; Jonathan A McCullers; Evan J Anderson; Richard G Wunderink; Wesley H Self; Anna Bramley; Seema Jain; Andrew T Pavia; Anne J Blaschke
Journal:  J Pediatric Infect Dis Soc       Date:  2018-02-19       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.